|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Taken together, our findings indicate that <i>MPO</i> SNP rs2333227 serves as a marker of enhanced risk for development of colorectal cancer.<b>Significance:</b> MPO polymorphisms are a guide for high risk and poor prognosis in patients colorectal cancer.<i>Cancer Res; 78(10); 2760-9.©2018 AACR</i>.
|
29540402 |
2018 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The myeloperoxidase (MPO) -463G>A (rs2333227) polymorphism has been linked with increased susceptibility to the development of various malignancies.
|
27197583 |
2016 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
We suggest that rs2333227 (MPO_ -463G/A) and rs854560 polymorphisms have a great predictive significance; they could probably be utilized as cancer predictors in the future.
|
23167629 |
2012 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Taken together, our findings indicate that <i>MPO</i> SNP rs2333227 serves as a marker of enhanced risk for development of colorectal cancer.<b>Significance:</b> MPO polymorphisms are a guide for high risk and poor prognosis in patients colorectal cancer.<i>Cancer Res; 78(10); 2760-9.©2018 AACR</i>.
|
29540402 |
2018 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The authors investigated associations of serum phospholipid n-3 and n-6 polyunsaturated fatty acids (PUFAs) and trans-fatty acids with prostate cancer risk, and whether myeloperoxidase G-463A (rs2333227) modified the associations in the Carotene and Retinol Efficacy Trial (CARET) (Seattle, Washington; Irvine, California; New Haven, Connecticut; San Francisco, California; Baltimore, Maryland; and Portland, Oregon, 1985-2003).
|
23535901 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
The authors investigated associations of serum phospholipid n-3 and n-6 polyunsaturated fatty acids (PUFAs) and trans-fatty acids with prostate cancer risk, and whether myeloperoxidase G-463A (rs2333227) modified the associations in the Carotene and Retinol Efficacy Trial (CARET) (Seattle, Washington; Irvine, California; New Haven, Connecticut; San Francisco, California; Baltimore, Maryland; and Portland, Oregon, 1985-2003).
|
23535901 |
2013 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
We suggest that rs2333227 (MPO_ -463G/A) and rs854560 polymorphisms have a great predictive significance; they could probably be utilized as cancer predictors in the future.
|
23167629 |
2012 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Associations between MPO -463 G to A genotype (rs2333227) and prostate cancer risk were only noted among men with aggressive cancer, with more than a 2-fold risk reduction among men with AA genotypes (OR = 0.4, 95% CI = 0.2-1.0); MnSOD was not associated with risk overall, but the MnSOD T to C (Val-9Ala, rs4880) polymorphism modified associations between risk of clinically aggressive prostate cancer and dietary iron intake (P for interaction = 0.02).
|
18296681 |
2008 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
Associations between MPO -463 G to A genotype (rs2333227) and prostate cancer risk were only noted among men with aggressive cancer, with more than a 2-fold risk reduction among men with AA genotypes (OR = 0.4, 95% CI = 0.2-1.0); MnSOD was not associated with risk overall, but the MnSOD T to C (Val-9Ala, rs4880) polymorphism modified associations between risk of clinically aggressive prostate cancer and dietary iron intake (P for interaction = 0.02).
|
18296681 |
2008 |
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The possible association between the presence of an MPO -463 G > A (rs2333227) polymorphism and cervical cancer risk.
|
29937309 |
2018 |
|
Chronic Kidney Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
Previous studies have shown that MPO -463G > A (rs2333227) might be associated with chronic kidney disease (CKD) susceptibility, but sample sizes of those studies are relatively small.
|
30278820 |
2018 |
|
Tumor Cell Invasion
|
|
0.010 |
GeneticVariation
|
BEFREE |
Colorectal cancer cells with the rs2333227 TT genotype exhibited enhanced proliferation, migration, and invasion capacity <i>in vitro</i> and <i>in vivo</i> Mechanistically, we found that <i>MPO</i> SNP rs2333227 C to T mutation altered the binding affinity of the transcription factors AP-2α to the rs2333227 mutation region, sequentially enhancing expression levels of <i>MPO</i> and activating further IL23A-MMP9 axis-mediated oncogenic signaling.
|
29540402 |
2018 |
|
Cervix carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The possible association between the presence of an MPO -463 G > A (rs2333227) polymorphism and cervical cancer risk.
|
29937309 |
2018 |
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Taken together, our findings indicate that <i>MPO</i> SNP rs2333227 serves as a marker of enhanced risk for development of colorectal cancer.<b>Significance:</b> MPO polymorphisms are a guide for high risk and poor prognosis in patients colorectal cancer.<i></i>.
|
29540402 |
2018 |
|
Malignant tumor of cervix
|
|
0.010 |
GeneticVariation
|
BEFREE |
The possible association between the presence of an MPO -463 G > A (rs2333227) polymorphism and cervical cancer risk.
|
29937309 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
Taken together, our findings indicate that <i>MPO</i> SNP rs2333227 serves as a marker of enhanced risk for development of colorectal cancer.<b>Significance:</b> MPO polymorphisms are a guide for high risk and poor prognosis in patients colorectal cancer.<i></i>.
|
29540402 |
2018 |
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>MPO</i> rs2333227 polymorphism was positively associated with AD risk, especially under the AA+GA vs. GG and A vs. G genetic models (<i>P</i>=0.042, OR=1.719, 95%CI=1.017-2.906; <i>P</i>=0.041, OR=1.582, 95%CI=1.016-2.463).
|
29296208 |
2017 |
|
Essential Hypertension
|
|
0.010 |
GeneticVariation
|
BEFREE |
The purpose of this study was to investigate whether a common polymorphism -463G>A (rs2333227) in the promoter of myeloperoxidase (MPO) gene, an oxidant enzyme producing hypohalogenic radicals, is associated with the risk of essential hypertension (EH) in Russian population.
|
26431910 |
2015 |
|
Iron Overload
|
|
0.010 |
GeneticVariation
|
BEFREE |
We aimed to investigate the influence of haptoglobin (Hp) and myeloperoxidase (MPO - G463A; dbSNP rs2333227) gene polymorphisms on 78 sickle cell patients of a public hospital in the Federal District/Brazil with and without iron overload, to evaluate a possible association between these polymorphisms and clinical variability, response to treatment and prognosis.
|
24567965 |
2014 |
|
aggressive cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations between MPO -463 G to A genotype (rs2333227) and prostate cancer risk were only noted among men with aggressive cancer, with more than a 2-fold risk reduction among men with AA genotypes (OR = 0.4, 95% CI = 0.2-1.0); MnSOD was not associated with risk overall, but the MnSOD T to C (Val-9Ala, rs4880) polymorphism modified associations between risk of clinically aggressive prostate cancer and dietary iron intake (P for interaction = 0.02).
|
18296681 |
2008 |